TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06858319: A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.

Sponsor: Novartis Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 220 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$11,597,424

Rescue Site Savings

+$7,637,328

Unlock Full NCT06858319 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06858319 Rescue Dossier →